Showing posts with label Genetics. Show all posts
Showing posts with label Genetics. Show all posts

Wednesday, 2 June 2010

Illuminating the brain's bright future

In the 1920s Felix the Cat had a brilliant idea and a light bulb appeared over his head; thus was created the signature of an epiphany. But recent advances in neuroscience leave you wondering whether in the future we will be more familiar with light bulbs actually driving our thoughts and inspiration rather than just being a visual metaphor. Gero Miesenböck, currently Waynflete Professor of Physiology at Oxford University, has been pioneering work that uses light to control brain cells, a field known as optogenetics.

Our brain consists of approximately 100 billion neurons that, as Miesenböck lyrically describes, form “an intricate tapestry”. To understand how neuronal signalling drives our behaviour, he says, we need to tease apart the disparate contributions that each of the different populations of neurons make to our behaviour. Nobel laureate Francis Crick remarked in a famous article in 1979 that one thing scientists have dreamed about is a tool that would allow them to selectively activate or turn off certain groups of cells while leaving others unaffected. Twenty years later, he suggested how this might be achieved: with light and molecular engineering. And this is precisely what optogenetics does.

To understand this technique we have to go back to the 1990s when German biologist Peter Hegemann discovered that green algae, commonly found in ponds, respond to light by wagging their tail. This behaviour was intriguing because algae are unicellular creatures without eyes. Hegemann discovered that when light photons hit the protein coils packed in the algae’s cell membrane, a chemical reaction creates a tiny gap in the membrane, causing an ionic current to be produced and the algae’s tail to wag. The protein that allows this reaction with light is called channelrhodopsin and is comparable to rhodopsins found in our own eyes.

Meanwhile, Miesenböck and his colleagues, working in New York and later at Yale, wondered whether they could exploit a similar mechanism to control brain cells. They took light sensitive proteins like the photoreceptors of our eyes, transplanted them into neurons and, by simply shining a light on them, the team was able to activate the modified neurons, a first step towards neuronal control.

To exploit the full power of this method, however, the researchers needed to discover a way just to excite or inhibit selected populations of cells, and with genetic engineering they were able to achieve this. By harnessing the cunning of viruses or by creating genetically-modified mice and flies, it was possible to make expression of the rhodopsin-encoding gene specific to particular neurons, meaning that only those neurons would become active when illuminated.

The road to success for optogenetics was not easy. The first difficult step was to find out whether they were able to transplant the rhodopsin-containing photoreceptors of flies to other cells in a culture and activate them with a flash of light. Once they succeeded in doing this, the second, even more complicated challenge was to move from changing neuronal activity in a cell culture to changing the behaviour of a living being, in Miesenböck’s case the fruit fly. The promise became initially clear when Susana Lima, Miesenböck’s PhD student at the time, showed him the first baby steps taken by a fruit fly on command of light. Within 5 years, they had learned how to remote control a fly.

The technique is now so advanced there is a large volume of work looking at how brain cells control behaviour. Last year in Cell, Miesenböck and his team exposed the learning mechanisms of a fly by creating false memories (1). They placed a fly in a narrow chamber, half of which smelled of an old tennis shoe, the other half of sweet fruit. By observing how much time the fly spent on either side, the researchers were able to work out which was the fly’s preferred smell. When this location was later paired with a memorable, aversive signal – a painful electrical shock – the fly learned to avoid this location and spend more time on the opposite side of the chamber. From previous research, Miesenböck knew which neurons were involved in learning to associate the shock with an odour and could therefore directly target this system with optogenetics. By activating these cells with light when the fly was in the location of its preferred smell, Miesenböck’s team was able to provoke identical avoidance behaviour even though no electric shock was given. Thus, the fly learned from an experience it never had.

Might we be able to use this technique to control our minds in the future? Miesenböck thinks that it will be a while before optogenetics can be used in humans: “You would have to express a foreign gene in a targeted fashion and this is where the show-stopper currently lies”. While using this technique in humans may be a long way off, he does believe that optogenetic research in flies might nonetheless directly aid our understanding of the human brain because biology is generally conserved. “Nature rarely invents the wheel twice”.

For now, Miesenböck thinks the field should focus on blurring the boundaries between work in whole organisms and fine-scale research in cell cultures. They could make use of the fact that tissue in a cell culture can be treated as if it was still part of a functioning brain by activating the cells with flashes of light – a use of optogenetics that is currently underappreciated. “There will be room for brain-free neurobiology, where optogenetics provides the interface to allow researchers to really talk to and feed artificial information into neuronal systems”.

Miesenböck also advocates using light “to enable scientists to drive nervous systems outside their normal operating limits, because this is often where mechanisms reveal themselves”. Miesenböck’s team used this approach to investigate the origin of sex differences in flies. While male and female fly brains are very similar, they nonetheless display sex-specific courting behaviours. The gene that controls male courting behaviour is expressed in a very small number of neurons in the abdominal ganglia of the fly. By specifically targeting these cells with optogenetics and shining light onto this circuitry, Miesenböck’s team was able to produce male courting behaviour in all the flies, even the females (2). Thus, they were able to show that females possess a bisexual brain containing a motor programme necessary for male courtship behaviour, but do not activate it because the neuronal commands required for the behaviour are absent.

With the ability to dissect neuronal functioning in the healthy brain, optogenetics might also hold potential to help understand the exact mechanisms that cause neurological and psychiatric diseases such as depression and schizophrenia and even help treat them. For example, Karl Deisseroth and his team at Stanford University in California published a study in Science last year that used optogenetics in rats to investigate directly how deep brain stimulation might alleviate symptoms of Parkinson’s Disease, something that had previously been poorly understood (3).

Thus, despite the difficulties in applying the method to humans, Miesenböck is hopeful: “With optogenetics we can really identify the players that are responsible for particular behaviour and that may give us knowledge for targets of more conventional treatment. Then conventional treatment can become more effective and cleaner.”

References:
1. Claridge-Chang et al., 2009. Writing memories with light-addressable reinforcement circuitry. Cell 139:405- 415.
2. Dylan Clyne & Miesenböck, 2008. Sex-Specific Control and Tuning of the Pattern Generator for Courtship Song in Drosophila. Cell 133:354-363.
3. Gradinaru et al., 2009. Optical deconstruction of parkinsonian neural circuitry. Science 324:354-359.

This article appeared in 'Phenotype'. Here you can read the magazine its entirety.

A shorter, related post can be found on my blog here.

Tuesday, 7 July 2009

A simple drug for Alzheimer's disease?

Alzheimer's disease is the most common form of dementia, affecting 1 in 10 people over the age of 65 and 1 in 5 over the age of 80. This truly debilitating disease gradually reduces the patient to living in the past without the ability to make new memories, and is not only devastating for the patients and their families, but is also a heavy burden on our health system.

Researchers at the Florida Alzheimer's Disease Research Center may have found that one of the most harmless and commonplace 'drugs', caffeine, may have a positive effect on the cognitive abilities of patients who suffer from the disease. The research group studied 55 mice that were genetically modified to develop Alzheimer's disease. After the mice had developed the disease, half of the group was given 500 milligrams of caffeine – the equivalent of 5 cups of regular coffee - in their drinking water every day. The other half did not get any caffeine. The researchers showed that caffeine improved memory and thinking abilities significantly after only two months of treatment, and were able to perform as well as healthy mice of the same age. The mice that had not received treatment continued to deteriorate.

The main cause of Alzheimer's disease is the formation of tangles and plaques in the brain, causing brain cells to die and communication pathways to be disrupted and destroyed. Broadly speaking, there are two enzymes responsible for the formation of the plaques and tangles, tau and amyloid beta/β. Plaques are formed by large clumps of amyloidβ in the spaces between cells. Tangles are formed by tau. Tau, normally a building block of the transport system of a cell, starts to disintegrate this transport system as a result of a chemical change, causing damage to the cell's nutrition- and communication, eventually leading to the death of the cell.

In patients with Alzheimer’s disease, an abnormally high level of amyloidβ is found in the blood. The study published in the Journal of Alzheimer's Disease this week shows a remarkable decrease – nearly 50% – in the abnormal levels of this protein in the blood and brains of mice treated with caffeine. Thus, the improvement in memory and thinking thus seems to be related to the decrease of tangles and plaques in the brain.

Although mice, needless to say, are quite different from humans – and the development of the disease is different in both species – these results are really promising. The first very preliminary results from tests in elderly people indicate that levels of amyloidβ decrease rapidly after treatment with caffeine.

But don’t think you will be able to boost your memory by drinking coffee; when healthy mice drank 500 milligrams of coffee each day, their memory did not improve. So though we may have a wonder drug to cure one of the most debilitating diseases of our time, alas, we still haven’t found a way to become smarter.

Wednesday, 29 April 2009

The autistic gene

When my nephew was 9 years old he was obsessed with taps. Whenever he saw a tap, he had to turn it on. He has always been very good at drawing, he likes to draw even the smallest details you and I would miss. And if you want to know what day of the week March 23 is in 2050, just ask him and you will get the answer within seconds. He is a grown man now. He does not have many friends, he prefers being on his own. He has autism.

This week a study in Nature revealed evidence for a link between a specific gene and the development of autism.

Autism is a so-called neurodevelopmental disorder whereby the normal growth patterns of the central nervous system and the brain are altered. This abnormal development often results in learning disabilities, and social and emotional problems.

Over the years, there has been a lot of speculation as to what causes the brain and nervous system of autistic people to develop in a different way compared to the normal development. This has led to outrageous speculations about the lack of oxygen at birth, and to masses of people refusing to vaccinate their children with the MMR vaccine to protect them from getting measles, mumps and rubella, because of a falsely assumed link between autism and the vaccine for which no-one ever found any convincing evidence.

More controlled research has recently led to the discovery that the abnormal development seen in autism is especially affecting frontal regions of the brain. With the help of these regions we make plans and decisions and they do also support our interactions with other people. Another important discovery about the structure of the autistic brain is that there are a smaller number of pathways used for communication within the frontal lobes and between the frontal lobes and other regions in the brains of autistic people.

The article in Nature describes how in a group of 10.000 subjects consisting of autistic patients and their families, common genetic variants on 5p14.1 were identified. This gene has been tentatively linked with autism before, and this study confirms its importance in autism.

Thus, this study does not only show us the gene involved in autism, we can also derive from it that the class of genes to which this specific gene belongs is important for the normal development of structure and communication pathways in the healthy human brain.

Having a gene to hold accountable for autism does pose some ethical questions; with genetic screening it is possible to look at the genetic make-up of the unborn child and you could, based on the results, decide whether to proceed the pregnancy, or that, maybe, it's better for everybody not to have the child ... But given that the development of autism is not solely dependent on the genetic expression and there is a likely chance your child will be completely healthy, do you really want to make these decisions? And do we really want to rid the world of the Lewis Carrolls, Glenn Goulds, Beethovens, Vincent van Goghs and Wittgensteins, all of whom are suspected to have had autistic traits?